Medicure Inc

0.780000.00Vol 6551Y Perf 27.66%
Dec 2nd, 2021 12:04
BID0.0000 ASK0.0000
Open0.6840 Previous Close0.7800
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.20
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+     28.86
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.72 
Earnings Rating
Market Cap8.00M 
Earnings Date
11th May 2021
Alpha-0.03 Standard Deviation0.17
Beta1.00 

Today's Price Range

0.68400.7800

52W Range

0.64001.5914

5 Year PE Ratio Range

-0.500088.900

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.50%
1 Month
1.96%
3 Months
-11.12%
6 Months
-21.21%
1 Year
27.66%
3 Years
-83.47%
5 Years
-88.20%
10 Years
0.00%

TickerPriceChg.Chg.%
MCUJF0.78000.00000.00
AAPL163.76-1.0100-0.61
GOOG2 875.5343.17001.52
MSFT329.49-0.5900-0.18
XOM61.281.49002.49
WFC48.911.70003.60
JNJ157.09-0.9900-0.63
FB310.39-0.2100-0.07
GE95.232.23002.40
JPM161.213.32002.10
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.30
0.05
0.08
-57.20
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
53.40
-43.30
-23.60
-11.10
-47.28
RevenueValueIndustryS&P 500US Markets
9.73M
0.95
-21.55
-20.97
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.08-
Q02 2020-0.00-
Q01 2020--0.10-
Q04 2019--0.74-
Q03 2019--0.03-
Q02 2019--0.04-
Q01 2019--0.14-
Q04 2018-0.07-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume655
Shares Outstanding10.25M
Shares Float5.24M
Trades Count3
Dollar Volume463
Avg. Volume6.45K
Avg. Weekly Volume1.35K
Avg. Monthly Volume2.61K
Avg. Quarterly Volume2.60K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Medicure Inc

Medicure Inc is a specialty pharmaceutical company. It is involved in research, clinical development, and commercialization of human therapeutics for United States hospital market. Its main focus is on sale and marketing of its drug Aggrastat which is a glycoprotein GP IIb/IIIa receptor antagonist, is used for the treatment of acute coronary syndrome including unstable angina. The firm derives the majority of its revenue geographically from the United States.

CEO: Albert D. Friesen

Telephone: +1 204 487-7412

Address: 2-1250 Waverley Street, Winnipeg R3T 6C6, MB, CAN

Number of employees: 64

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

64%36%

News